Pro Medicus Stock EBITDA
| PME Stock | 221.75 7.13 3.32% |
Pro Medicus fundamentals help investors to digest information that contributes to Pro Medicus' financial success or failures. It also enables traders to predict the movement of Pro Stock. The fundamental analysis module provides a way to measure Pro Medicus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pro Medicus stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 120.8 M | 126.8 M |
Pro | EBITDA |
Pro Medicus Company EBITDA Analysis
Pro Medicus' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Pro Medicus EBITDA | 120.76 M |
Most of Pro Medicus' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pro Medicus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Pro Ebitda
Ebitda |
|
According to the company disclosure, Pro Medicus reported earnings before interest,tax, depreciation and amortization of 120.76 M. This is much higher than that of the Health Care Technology sector and significantly higher than that of the Health Care industry. The ebitda for all Australia stocks is notably lower than that of the firm.
Pro EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pro Medicus' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pro Medicus could also be used in its relative valuation, which is a method of valuing Pro Medicus by comparing valuation metrics of similar companies.Pro Medicus is currently under evaluation in ebitda category among its peers.
Pro Fundamentals
| Return On Equity | 0.51 | ||||
| Return On Asset | 0.31 | ||||
| Profit Margin | 0.51 % | ||||
| Operating Margin | 0.73 % | ||||
| Current Valuation | 23.02 B | ||||
| Shares Outstanding | 104.5 M | ||||
| Shares Owned By Insiders | 51.20 % | ||||
| Shares Owned By Institutions | 14.17 % | ||||
| Price To Book | 123.44 X | ||||
| Price To Sales | 143.48 X | ||||
| Revenue | 161.5 M | ||||
| Gross Profit | 126.79 M | ||||
| EBITDA | 120.76 M | ||||
| Net Income | 82.79 M | ||||
| Total Debt | 2.07 M | ||||
| Book Value Per Share | 1.80 X | ||||
| Cash Flow From Operations | 86.78 M | ||||
| Earnings Per Share | 0.80 X | ||||
| Target Price | 152.71 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 23.17 B | ||||
| Total Asset | 257.43 M | ||||
| Retained Earnings | 173.36 M | ||||
| Working Capital | 172 M | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 257.43 M | ||||
| Last Dividend Paid | 0.4 |
About Pro Medicus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pro Medicus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pro Medicus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pro Medicus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pro Stock Analysis
When running Pro Medicus' price analysis, check to measure Pro Medicus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pro Medicus is operating at the current time. Most of Pro Medicus' value examination focuses on studying past and present price action to predict the probability of Pro Medicus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pro Medicus' price. Additionally, you may evaluate how the addition of Pro Medicus to your portfolios can decrease your overall portfolio volatility.